Food and Drug Administration (FDA)

Battle Lines Drawn over Biosimilar Application and Patent Disclosure Process

Battle Lines Drawn over Biosimilar Application and Patent Disclosure Process
Share

By Jordan Paradise The Biosimilars Price Competition and Innovation Act of 2009 (BPCIA) introduced a long-awaited, and highly-supported, abbreviated route to market for “biosimilar” and “interchangeable” biologic products. The goal was to create incentives for development and reduce health care costs in the same way that previous legislation had accomplished in the generic arena over […]

Share

Continue Reading »

Last Week for Comments on Proposed FDA Guidance on 3-D Printed Medical Devices

Last Week for Comments on Proposed FDA Guidance on 3-D Printed Medical Devices
Share

By Nicole Stuver Three-dimensional scanning, modeling, and printing have become an emerging field of diagnosing and treating maladies.  This technology has enabled advances in neurology, dentistry, orthodontics, orthopedics, cardiology, oncology and other fields of practice.  These new technologies are revolutionary particularly because they have the capability to be customized for each individual patient.  President Obama […]

Share

Continue Reading »

What’s Next If the FDA Holds the Line on Social Media?

What’s Next If the FDA Holds the Line on Social Media?
Share

Cross-Posted at Bill of Health Earlier this week, the Food and Drug Administration announced that it was reopening the comment periods for the two draft guidances on the use of social media to promote prescription drugs and medical devices that it released in June:  Internet/Social Media Platforms with Character Space Limitations: Presenting Risk and Benefit Information for […]

Share

Continue Reading »

Seton Hall Law Alum David Gibbons on Hospira v. Burwell and FDA’s Authority to Order Drug Recalls

Share

Last week, Seton Hall Law alum David Gibbons of Hyman, Phelps & McNamara published a blog post at the firm’s FDA Law Blog on a very interesting legal question, whether a court can order the FDA to order a drug manufacturer to recall a drug. In a suit brought by Hospira challenging the FDA’s approval of […]

Share

Continue Reading »

Ebola Outbreak Shines a Light on Compassionate Use

Ebola Outbreak Shines a Light on Compassionate Use
Share

The Ebola outbreak, which has claimed nearly 1,000 lives since its emergence in West Africa in December 2013, has brought renewed attention to policies surrounding the “compassionate use” of unapproved medications – i.e., the provision of unapproved medications to individuals outside the context of clinical trials.   The issue rose to the forefront early last week […]

Share

Continue Reading »